V-Bio Ventures

V-Bio Ventures is a Belgian life-sciences venture capital firm based in Ghent (Gent), Flanders, Belgium aEUR" the Flemish biotech-cluster city that is home to the VIB / Vlaams Instituut voor Biotechnologie research institute, Ghent University Hospital, and one of Europe's most productive biomedical-research clusters. The firm invests in start-up and early-stage companies based in Europe, focusing on technologies providing transformative life-sciences solutions across drug discovery, precision medicine, agbiotech, industrial biotechnology, and adjacent biomedical themes. V-Bio Ventures was co-founded in 2015 by Christina Takke and Willem Broekaert alongside partners, with roots in the VIB research commercialisation ecosystem. The firm has raised multiple institutional funds (V-Bio Ventures Fund I in 2015 at EUR 75 million, V-Bio Ventures Fund II in 2020 at EUR 110 million, V-Bio Ventures Fund III in 2023 at approximately EUR 170 million+) with aggregate AUM approaching EUR 350-400 million across vintages. Notable portfolio companies have included Aelin Therapeutics, Aphea.Bio, Aquaculture Stewardship Council, Confo Therapeutics, Exevir Bio, Precirix, and many other European life-sciences start-ups producing multiple exits.